We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

A Study of HMPL-523 in Relapsed or Refractory Hematologic Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02503033
Recruitment Status : Unknown
Verified September 2020 by Hutchmed ( Hutchison Medipharma Limited ).
Recruitment status was:  Active, not recruiting
First Posted : July 20, 2015
Last Update Posted : September 11, 2020
Iqvia Pty Ltd
Information provided by (Responsible Party):
Hutchmed ( Hutchison Medipharma Limited )

Brief Summary:

The purpose of this study is to evaluate the safety and tolerability of HMPL-523 administered to patients with relapsed or refractory Hematologic Malignancies

To determine the maximum tolerated dosage/recommended phase 2 dosage and characterize the dose limited toxicities associated with HMPL-523 when administered to patients with relapsed or refractory Hematologic Malignancies

Condition or disease Intervention/treatment Phase
Hematologic Malignancies Drug: HMPL-523 Phase 1

Detailed Description:

There are two stages in this study: a dose-escalation stage (stage 1) and a dose-expansion stage (stage 2).

Dose-escalation stage (stage 1). The conventional 3+3 design (3 patients per dose cohort, with the potential to add additional 3 patients to the same cohort to further evaluate toxicity) will be applied for dose escalation and maximum tolerated dosage determination. Approximately 18 to 27 evaluable patients will be enrolled. The actual number of patients depends on the dose limited toxicities situation as well as the maximum tolerated dosage reached at this stage.

Dosing will include QD (quaque die) and bis in die (BID) cohorts. A cycle of study treatment will be defined as 28 days of continuous dosing.

Dose-expansion stage (stage 2). In this stage, approximately 40 patients with B-cell Non-Hodgkin's Lymphomas or Chronic Lymphocytic Leukemia will be enrolled with 600mg once daily as starting dose. The tumor types of the expansion stage are restricted to Chronic lymphocytic leukemia/ small lymphocytic lymphoma (CLL/SLL), Mantle cell lymphoma (MCL), Follicular Lymphoma (FL) (Grade 1-3a), Marginal zone lymphoma (MZL) and Waldenstrom's macroglobulinemia / Lymphoplasmacytic lymphoma (WM/LPL). Subjects will receive HMPL-523 600mg once daily with every 28-day treatment cycle until disease progression, death, or intolerable toxicity, whichever comes first.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 78 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of HMPL-523 in Patients With Relapsed or Refractory Hematologic Malignancies
Actual Study Start Date : November 2015
Estimated Primary Completion Date : December 2020
Estimated Study Completion Date : March 2021

Arm Intervention/treatment
Experimental: HMPL-523

Oral administration, at a dose of 100, 200, 400, 600, 800 and 1000mg once daily or 300mg and 400mg twice daily at Dose-escalation stage.

At the Dose-expansion stage, HMPL-523 600mg will be dosed once daily.

Drug: HMPL-523
Oral administration, once daily

Primary Outcome Measures :
  1. dose limited toxicities evaluated with NCI CTCAE v4.03 [ Time Frame: within 28days after the first dose ]
    Incidence of dose limited toxicities and associated dose of HMPL-523

Secondary Outcome Measures :
  1. maximum plasma concentration calculated with Blood samples [ Time Frame: within 29 days after the first dose ]
    Blood samples will be taken to measure the levels of study drug

  2. time to reach maximum concentration calculated with Blood samples [ Time Frame: within 29 days after the first dose ]
    Blood samples will be taken to measure the levels of study drug

  3. Objective response rate [ Time Frame: within 30 days after the last dose ]
    the proportion of subjects who have a Complete Response or Partial Response

  4. adverse events evaluated by NCI CTCAE v4.03 [ Time Frame: from the first dose to within 30days after the last dose ]
    Incidence of adverse events and associated dose of HMPL-523

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Signed Informed Consent Form.
  2. Ability to comply with the protocol.
  3. Age>=18 years.
  4. ECOG performance status of 0 or 1.
  5. Histologically relapsed or refractory chronic lymphocytic leukemia, lymphoma, multiple myeloma(MM) In the dose expansion stage, the tumor types are restricted to relapsed or refractory CLL/SLL, MCL, FL (Grade 1-3a), MZL and WM/LPL.
  6. Have failed at least one prior therapy or patients who are unable to tolerate standard therapy or no curative therapy or therapy of higher priority exists.
  7. In the dose-expansion stage, patients must have measurable disease for objective response assessment.

    NOTE: measurable disease with FL, MCL, MZL, LPL, or SLL defined as at least 1 bi-dimensionally measurable lesion (>1.5 cm in its largest dimension by computerized tomography [CT] scan)., as defined in appendix 9.

  8. Expected survival of more than 24 weeks as determined by the investigator.
  9. Male or female patients of child-bearing potential must agree to use double barrier contraception, condoms, sponge, foams, jellies, diaphragm or intrauterine device (IUD), contraceptives (oral or parenteral), Implanon®, injectables or other avoidance of pregnancy measures during the study and for 90 days after the last day of treatment. Post-menopausal females (>45 years old and without menses for >1 year) and surgically sterilized females are exempt from this criterion.

Exclusion Criteria:

  1. Patients with primary CNS lymphoma.
  2. Known active central nervous system or leptomeningeal lymphoma.
  3. Any of the following laboratory abnormalities:

    1. Absolute neutrophil count<1.5×109/L
    2. Hemoglobin <80g/L.
    3. Platelet<75 ×109/L. NOTE: in expansion stage patients with cell counts below the thresholds listed above may be considered eligible if in the investigators opinion the reason is believed to be due to bone marrow infiltration. The investigator will discuss the eligibility of such patients with the sponsor and only upon approval (confirmed in writing) by the sponsor will a patient be enrolled in the study.
  4. Inadequate organ function, defined by the following:

    1. Total bilirubin >1.5the ULN with the following exception:

      Patients with known Gilbert disease who have serum bilirubin level ≤3 the ULN and normal AST/ALT may be enrolled.

    2. AST and/or ALT > 2.5 the ULN with the following exception:Patients with documented disease infiltration of the liver may have AST and/or ALT levels ≤ 5 the ULN.
    3. Serum creatinine > 1.5 the ULN or estimated creatinine clearance < 50 mL/min.
    4. Serum amylase or lipase > the ULN.
    5. Triglycerides and/or cholesterol >1.5 the ULN.
    6. International normalized ratio (INR)>1.5 the ULN or activated partial thromboplastin time (aPTT)>1.5 the ULN.

    For patients requiring anticoagulation therapy with warfarin, a stable INR between 2-3 is required. If anticoagulation is required for a prosthetic heart valve, then INR should be between 2.5-3.5 for eligibility NOTE: patients may be considered for the study if liver or kidney function is impaired, but this impairment is believed to be a result of the patient's underlying disease. The investigator will discuss the eligibility of such patients with the Sponsor and only upon approval (confirmed in writing) by the Sponsor will a patient be enrolled in the study.

  5. Subjects with presence of clinically detectable second primary malignant tumors at enrollment, or other malignant tumors within the last 2 years (with the exception of radically treated basal cell or squamous cell carcinoma of the skin, in situ cervix, or in situ breast cancer).
  6. Any anti-cancer therapy, including chemotherapy, hormonal therapy, biologic therapy, or radiotherapy within 3 weeks prior to initiation of study treatment.
  7. Herbal therapy ≤1 week prior to initiation of study treatment.
  8. Prior use of any anti-cancer vaccine.
  9. Prior treatment with any SYK inhibitors (e.g. Fostamatinib).
  10. Prior administration of radioimmunotherapy 3 months prior to initiation of study treatment.
  11. Taking strong CYP3A inhibitors, and inducers and drugs metabolized by CYP3A, 2B6 and 1A2 that are identified as narrow therapeutic drugs within 7 days or 3 half-lives, whichever is longer, prior to administration of the first dose of study drug (refer to Appendix 15).
  12. Adverse events from prior anti-cancer therapy that have not resolved to Grade ≤1, except for alopecia.
  13. Prior autologous transplant within 6 months prior to first dose of study drug.
  14. Prior allogeneic stem cell transplant within 6 months prior to initiation of study treatment or with any evidence of active graft versus host disease or requirement for immunosuppressants within 28 days prior to initiation of study treatment.
  15. Clinically significant active infection (pneumonia)
  16. Major surgical procedure within 4 weeks prior to initiation of study treatment.
  17. Clinically significant history of liver disease, including cirrhosis, current alcohol abuse, or current known active infection with HIV, hepatitis B virus (HBV), or hepatitis C virus (HCV).

    Active infection is defined as requiring treatment with antiviral therapy or presence of positive test results for hepatitis B (hepatitis B surface antigen and/or total hepatitis B core antibody) or HCV antibody.

    Patients who test positive for hepatitis B core antibody are eligible only if test results are also positive for hepatitis B surface antibody and polymerase chain reaction (PCR) is negative for HBV DNA.

    Patients who are positive for HCV serology are only eligible if testing for HCV RNA is negative.

  18. Pregnant (positive pregnancy test) or lactating women.
  19. New York Heart Association (NYHA) Class II or greater congestive heart failure.
  20. Congenital long QT syndrome or QTc > 450 msec.
  21. Currently use medication known to cause QT prolongation or Torsades de Pointes (http:// www.crediblemeds.org)
  22. History of myocardial infarction or unstable angina within 6 months prior to initiation of study treatment.
  23. History of stroke or transient ischemic attack within 6 months prior to initiation of study treatment.
  24. Inability to take oral medication, prior surgical procedures affecting absorption, or active peptic ulcer disease.
  25. Image evidence of gallstone or other bile duct disease within 6 months prior to initiation of study treatment.
  26. Treatment within a clinical study within 30 days prior to initiation of study treatment.
  27. Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding that, in the investigator's opinion, gives reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or renders the patient at high risk from treatment complications.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02503033

Layout table for location information
Australia, Australian Capital Territory
Canberra Hospital
Canberra, Australian Capital Territory, Australia
Australia, New South Wales
Border Medical Oncology Research Unit
Albury, New South Wales, Australia, 2640
Liverpool Hospital
Liverpool, New South Wales, Australia
Australia, Queensland
Townsville Hospital
Townsville, Queensland, Australia, 4814
Australia, South Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia
Australia, Victoria
Ballarat Regional Integrated Cancer Centre
Ballarat, Victoria, Australia, 3350
St Vincent's Hospital
Fitzroy, Victoria, Australia
Peninsula & South Eastern Haematology and Oncology Group
Frankston, Victoria, Australia
Barwon Health
Geelong, Victoria, Australia, 3220
Austin Hospital
Heidelberg, Victoria, Australia
Cabrini Health
Melbourne, Victoria, Australia, 3144
Australia, Western Australia
Royal Perth Hospital
Perth, Western Australia, Australia, 6000
Sponsors and Collaborators
Hutchison Medipharma Limited
Iqvia Pty Ltd
Layout table for investigator information
Study Director: Chen Yu, MD Hutchison Medi Pharma
Layout table for additonal information
Responsible Party: Hutchison Medipharma Limited
ClinicalTrials.gov Identifier: NCT02503033    
Other Study ID Numbers: 2015-523-00AU1
First Posted: July 20, 2015    Key Record Dates
Last Update Posted: September 11, 2020
Last Verified: September 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Additional relevant MeSH terms:
Layout table for MeSH terms
Hematologic Neoplasms
Neoplasms by Site
Hematologic Diseases